Reducing Immunosuppression in Older Kidney Transplant Patients (RIOT Trial)
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years old or older and have had only one kidney transplant (or two if the first was from a living donor).
- You do not have HIV.
- You are currently taking tacrolimus along with either mycophenolate mofetil or Myfortic (a type of mycophenolate).
- You have not had any rejection episodes since your transplant, and a recent biopsy (if done) shows no signs of rejection.
- Your blood tests show no antibodies that are strong enough to cause rejection (DSA and cPRA below certain levels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This trial tests a mycophenolate-based therapy for kidney transplant recipients who have no HLA-DQ mismatch. If you had your first kidney transplant 3-12 months ago without DQ mismatch and are on standard immunosuppressants, you may qualify.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study observes older kidney transplant patients (65+) who take a specific anti-rejection drug called tacrolimus once a day. It looks at their long-term outcomes to help improve care for people in this age group.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.